A hybrid approach based on ELECTRE III-genetic algorithm and TOPSIS method for selection of optimal COVID-19 vaccines

Roberto Louis Forestal | Shih-Ming Pi

Department of Information Management, Chung Yuan Christian University, Taoyuan, Taiwan

Correspondence
Roberto Louis Forestal, Department of Information Management, Chung Yuan Christian University, Taoyuan, Taiwan. Email: boolfrivie@gmail.com

Abstract
COVID-19 pandemic poses unprecedented challenges to the world health system, prompting academics and health professionals to develop appropriate solutions. Researchers reported different COVID-19 vaccines introduced by institutions and companies around the globe, which are at different stages of development. However, research developing an integrated framework for selecting and ranking the optimal potential vaccine against COVID-19 is minimal. This paper aimed to fill this gap by using a hybrid methodology based on ELimination Et Choice Translating REality III (ELECTRE III)–Genetic Algorithm (GA) and Technique of Order Preference Similarity to the Ideal Solution (TOPSIS) approach to select the optimal SARS-CoV-2 vaccine. ELECTRE III method yields a fathomable analysis of the concordance index, while GA is known for its ability to disaggregate decision-making preferences from holistic decisions. TOPSIS is preferred for picking an ideal and an anti-ideal solution. Thus, combining ELECTRE III-GA and TOPSIS is considered the best model to assess vaccines against the pandemic. The results confirm that the best vaccines rely on a high level of safety, efficacy, and availability. Our developed evaluation framework can help healthcare professionals and researchers gain research information and make critical decisions regarding potential vaccines against the disease.

KEYWORDS
COVID-19 vaccine, ELECTRE III, genetic algorithm, MCDM, TOPSIS

1 | INTRODUCTION

At the writing of this paper, more than 12 months have passed since World Health Organization (WHO) declared Covid-19 a pandemic. This pandemic has already caused the dramatic loss of millions of lives around the world. It poses unprecedented challenges to the global health system, urging the academic world and health professionals to work quickly on a solution. Studies on SARS-CoV-2 vaccine intentions showed that the majority of interviewees want to receive a COVID-19 vaccine. Given the need for a vaccine increasing demand, research institutions and pharmaceutical corporations used different methods to design potential COVID-19 vaccines platforms such as non-replicating viral vector, RNA-based, inactivated virus, protein subunit, and DNA-based vaccines. For example, Kumar et al. (2021) designed a promiscuous subunit vaccine from a pathogenic sequence, while Enayatkhani et al. (2021) developed a multi-epitope through a filtering pipeline. The reported vaccine of both studies was antigenic and capable of generating some robust immune responses.

Previous authors also used computational models, and multi-criteria decision-making (MCDM) approaches to widely inspect the novel coronavirus vaccine. For instance, Mohammed et al. (2020) used a decision matrix (DM) that embedded a mix of 10 evaluation criteria and 12 diagnostic models for COVID-19. An integrated MCDM method is proposed. The Technique of Order Preference Similarity to the Ideal Solution (TOPSIS) is applied for benchmarking and ranking purposes. At the same time, Entropy, used to calculate the weights of criteria. The results revealed that the benchmarking and selection problems associated with COVID-19 diagnosis models could be
effectiveness. The linear support vector machine (SVM) classifier is selected as the best diagnosis model for COVID-19 with the closeness coefficient value of 0.9899 for their case study data. Furthermore, the proposed methodology has solved the significant variance for each criterion in terms of ideal best and worst best value and the issue when specific diagnosis models have the same ideal best value.

However, our research acknowledges a substantial gap in the use of MCDM to select COVID-19 vaccines, as noted by Abdelwahab et al. (2021), despite the fact that Hezam et al. (2021) highlighting the importance of vaccine classification uses a neutrosophic analytic hierarchy process (AHP) and TOPSIS method to rank COVID-19 vaccine alternatives based on priority groups. Consequently, much of the existing literature focuses on the vaccine distribution process (Jakhar et al., 2021) instead of considering optimal vaccination approaches (Moore et al., 2021). Elimination Et Choice Translating Reality III (ELECTRE III) and genetic algorithm (GA) have reportedly outperformed common approaches in selecting optimal solutions while TOPSIS confirms its effectiveness in measuring the relative performance for each alternative (Aiello et al., 2013; Chen, 2021; Leyva-López & Fernández-González, 2003). Therefore, using a hybrid methodology based on ELECTRE-GA and TOPSIS approach can provide valuable insights into the optimised scenarios building (Marchetti & Wanke, 2020; Rohaninejad et al., 2015; Vafaeinejad, 2016). Concerning the motivation, our analysis also contributes to emerging literature studying COVID-19 vaccines, their safety, and effectiveness.

The remainder of the paper is structured as follows. Section 2 details the literature review. Section 3 presents the methodology used, including data selection and decision-making assessment. Section 4 and Section 5 present the empirical case study as well as results and discussion. Section 6 discusses managerial implications, while the final Section 7 concludes the analysis and elaborates on the limitations of the paper.

## 2 | STATE OF THE ART AND PROBLEM STATEMENT

### 2.1 | COVID-19 vaccine development and effectiveness

The novel COVID-19 pandemic caused by SARS-CoV-2 is a public-health emergency of international concern, thus calling for the development of a safe and effective vaccine to protect against the infection. It is essential to assess people’s intention to be vaccinated. Studies such as Faase and Newby (2020) and Head et al. (2020) conducted an online survey to examine the role of perceived risk, media coverage, and vaccination intentions among thousands of respondents. Findings revealed that the majority of interviewees were at least moderately concerned about a widespread COVID-19 outbreak. Worrying about the epidemic and closely monitoring media coverage were consistent forecasting parameters of health protection behaviours and vaccination intentions. With growing demand, the availability of a COVID-19 vaccine is touted as the solution to controlling the current COVID-19 pandemic, reducing the number of infections and deaths, and facilitating the resumption of our previous lifestyle (Abdullahi et al., 2021; Begum et al., 2021).

Scholars reported that many research institutions and pharmaceutical companies have already embarked on the race to develop COVID-19 vaccines, which involved the adaptive immune system. Their analysis recurred to immunoinformatics and advocated a sequence analysis of the pathogenic strains of SARS-CoV-2 to design vaccine candidates. These vaccine candidates may provide meaningful, timely directives for an effective vaccine against SARS-CoV-2 (Chen et al., 2021; Kumar et al., 2021; Oyarzun et al., 2021). Moreover, SARS-CoV-2 spike glycoprotein followed by epitopes’ use in constructing a multi-epitope peptide vaccine construct (MEPVC) is also an attractive candidate for a vaccine, antibodies, and inhibitor development because of the many roles it plays in attachment, fusion, and entry into the host cell. The MEPVC revealed robust host immune system simulation with high immunoglobulins, cytokines, and interleukins (Enayatkhani et al., 2021; Saha et al., 2021).

Other researchers designed and presented different kinds of vaccines against the novel coronavirus. For instance, Khurana et al. (2021) and Malabadi et al. (2021) proposed a development framework of a potential COVID-19 vaccine based on nanotechnology. They highlight the utility of nanomedicine in alleviating the COVID-19 health crisis. In addition, it is also crucial to mention that previous researchers argued the need to optimise SARS-CoV-2 vaccine confidence, availability, and efficacy. For example, Mehrrota et al. (2021) provide a set of clinical endpoints based on clinical and statistical reasoning to facilitate a harmonised assessment and comparison of the efficacy of novel coronavirus vaccines. Ensuring public confidence in vaccine safety and effectiveness is also crucial to facilitate uptake. Bartsch et al. (2020) apply a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination and reveal that the vaccine efficacy has to be at least 60% when vaccination coverage is 100%. Moreover, to extinguish an ongoing epidemic, the vaccine efficacy has to be at least 60% when coverage is 100% and at least 80% when coverage drops to 75% to reduce the peak by 85–86%, 61–62%, and 32% when vaccination occurs after 5, 15, and 30% of the population, respectively, have already been exposed to COVID-19 coronavirus. A vaccine with an efficacy between 60 and 80% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverage.

### 2.2 | Multiple criteria decision making

So far, we have displayed studies—primarily qualitative research—examining the demand, availability, and efficacy of COVID-19 vaccines. Previous authors also used the MCDM approach, which involves multiple attributes when dealing with COVID-19 pandemic and vaccination decisions (Batur Sir, 2021; Clemente-Suárez et al., 2021; Ni et al., 2021). Mohammed et al. (2020) used a decision
matrix (DM) that embedded a mix of 10 evaluation criteria and 12 diagnostic models for COVID-19. An integrated MCDM method is proposed where TOPSIS is applied for the benchmarking and ranking purpose while Entropy is used to calculate the weights of criteria. The results revealed that the benchmarking and selection problems associated with COVID-19 diagnosis models could be effectively solved using the integration of Entropy and TOPSIS. The linear SVM classifier is selected as the best diagnosis model for COVID-19 with a closeness coefficient value of 0.9899 for their case study data. Furthermore, the proposed methodology has solved the significant variance for each criterion in terms of ideal best and worst best value, besides issues when specific diagnosis models have the same ideal best value.

Based on available published evidence and clinical practice, Sayan et al. (2020) evaluated diagnostic tests of coronavirus disease (COVID-19) by MCDM methods, namely, fuzzy preference ranking organisation method for enrichment evaluation (fuzzy PROMETHEE) and fuzzy TOPSIS. Several parameters such as computerised tomography of the chest, CoV-19 antigen detection, and chest X-ray were evaluated by fuzzy linguistic scale to compare the diagnostic tests. This scale consists of selected parameters that possessed different weights, determined by the experts’ opinions of the field. The results indicated that the most effective diagnosis method of COVID-19 was chest CT. It is interesting to note that the methods consistently used in diagnosing viral diseases were ranked in second place for the diagnosis of COVID-19. Angelis et al. (2021) advocate the need for an MCDM approach to assessing the value of COVID-19 vaccines, calling for clinical, manufacturing, and cost aspects to be complemented with societal value considerations to inform decisions on development, reimbursement, and pricing of vaccines. Two important implications can be drawn from the results of this study.

First, the value of COVID-19 vaccines should be estimated against other health interventions, which can be informed by large-scale surveys of public preferences with established methodologies such as discrete choice experiments. Second, vaccine procurement costs could be used to derive cost-to-value ratios to inform resource allocation decisions within a fixed budget, similar to a portfolio optimisation approach. In addition, Hezam et al. (2021) highlight the need to identify priority groups when allocating COVID-19 vaccine doses since they assumed it is almost impossible to vaccinate everyone. Their methods include the neutrosophic AHP and TOPSIS. Neutrosophic AHP has been used to evaluate criteria related to age, health status, a woman’s status, and the kind of job. In contrast, TOPSIS has been employed to rank the COVID-19 vaccine alternatives. Their results indicate that the most suitable vaccine for patients and health workers prioritises other alternative vaccines.

Although much work has been done on the novel coronavirus, obtaining an integrated solution to limit the current COVID-19 disease remains challenging. Many studies conducted so far resulted in the urgent need to develop vaccines. Still, less has proposed a comprehensive framework to select and rank those potential vaccines candidates. Our research aims to apply a hybrid methodology based on ELECTRE III-Genetic Algorithm and the TOPSIS approach to select and outclass the best SARS-COV-2 vaccines.

## 3 | METHODOLOGY

This section discusses one possible methodology for assessing COVID-19 candidate vaccines using indicators. Following Aiello et al. (2013) and Majumder, Biswas, and Majumder et al. (2020), our research applied ELECTRE-GA and TOPIS approaches to selected and outranked candidate vaccines in clinical evaluation aiming at providing active acquired immunity to the novel coronavirus.

### 3.1 | Selection of criteria

Identifying appropriate criteria for COVID-19 candidate vaccines is essential for reliable outcomes. We examined several criteria sets proposed by World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), Coalition for Epidemic Preparedness Innovations (CEPI), and Gavi, the Vaccine Alliance. Those indicators are as follows:

#### 3.1.1 | Safety (SAF)

The FDA has issued guidance for the industry on the steps required for developing and ultimately licensing vaccines to prevent COVID-19—these are the same rigorous safety standards required for all vaccines. We imply that data from animal and human studies support no apparent risk of enhanced disease in vaccines by safety. Moreover, we also imply a lack of significant disease enhancement risk supported by clinical and/or pre-clinical data from relevant/suitable animal model(s) and unexpected severe findings that could require more investigations. To calculate vaccine safety, we use a crude ratio from Whelan (2009). This percentage is defined as the number of subjects exposed to a vaccine and experiencing a particular adverse event (such as fever, headaches, muscle pain), n, divided by the total number of subjects exposed to the vaccine, N, regardless of the duration of follow-up:

\[
\text{Crude rate (CR)} = \frac{n}{N} \times 100
\]

\[
\text{Safety rate (SR)} = 100 - CR
\]

#### 3.1.2 | Efficacy (VEF)

An efficacious COVID-19 vaccine could reduce the likelihood of infection of an individual, severity of disease in an individual, or degree of transmission within a population. In other words, it refers to the percentage reduction in the incidence of the disease in a vaccinated
group compared to an unvaccinated group under optimal conditions (Nichols et al., 2018). We use the following equation from Orenstein et al. (1985) to estimate vaccine efficacy:

\[
\text{Vaccine Efficacy (VEF)} = \frac{\text{ARU} - \text{ARV}}{\text{ARU}} \times 100
\]

where ARU is the attack rate of COVID-19 disease in the unvaccinated population, and ARV relates to the attack rate of the disease in the vaccinated population.

### 3.1.3 | Effectiveness (EFF)

Once the efficacy of a vaccine has been asserted, determining its effectiveness is essential to establish the vaccine’s uptake. Efficacy determines if the vaccine works, whereas effectiveness monitors the benefits of vaccination for the community. Vaccine effectiveness refers to preventing COVID-19 disease depending on its potency and proper administration to individuals capable of responding (Andrew & McNeil, 2021). It can be measured by considering the percentage of COVID-19 cases vaccinated (PCV), and the proportion of the population vaccinated (PPV) following Cohen et al. (2007).

\[
\text{Vaccine effectiveness (EFF)} = \frac{1 - (\text{PCV}(1 - \text{PPV}))}{\text{PPV}(1 - \text{PCV})}
\]

### 3.1.4 | Stability (STA)

Stability data are sufficient to assure delivery of dose to be tested. The stability of vaccines has a significant impact on the success of immunisation programmes worldwide. Optimising the use of vaccines depends heavily on maintaining optimal storage conditions. A vaccine is now expected to remain stable at standard refrigerator temperatures of 2–8°C (36–46 °F) for an average period of 1 week while shipping and long-term storage conditions are expected to remain at standard freezer temperatures of −20°C (−4 °F; Dadari & Zgibor, 2021; Dumpa et al., 2019; World Health Organization, 2018). However, some vaccines are sensitive to freezing, some to heat and others to light. Therefore, replacing a traditional models of vaccine stability with a version that yielded cost-saving appears to be more appropriate in appraising vaccine stability as Lee et al. (2017) proposed. This refers to the relative stability \( r \) of the vaccine \( i \), which is the ratio between the minimum costs associated with other vaccines and vaccine \( i \). PC, TC, and SC refer to procurement, transport, and storage costs, respectively.

\[
\text{Relative stability } (r) = \frac{m}{\text{Cost}_i}
\]

\[
\text{Cost}_i = \text{PC}_i + \text{TC}_i + \text{SC}_i
\]

\[
m = \text{Min}(\text{Cost}_i)
\]

The proposed set of indicators is organised into measurement units and information sources, as shown in Table 1.

An evaluation of coronavirus vaccine candidates has been performed using two multi-criteria approaches. The first one is based on ELECTRE III, whose first version was proposed by Bernard Roy and his colleagues at the SEMA consultancy company. The ELECTRE III method was chosen in our work because it provides a simple and understandable analysis of the Concordance index. Indeed, the fundamental basis of the ELECTRE methodology is a pairwise comparison between alternatives using two types of indices: Concordance and Discordance. For each ordered pair of options (A, B), Concordance and Discordance indices are assigned. A Concordance index referred to the measurement of the arguments in favour of A outranks B, and a Discordance index may shed some doubt upon the latter statement (Figueira et al., 2016). In other words, this method aims to obtain a subset or kernel N of project options such that any action which is not in N is outranked by at least one action in N (Roy, 2013).

### 3.2 | ELECTRE III-Genetic algorithm model

#### 3.2.1 | Genetic algorithm

GA are the heuristic search and optimisation techniques that mimic natural evolution. This algorithm is developed with the

| Criteria and abbreviation | Brief definition | Measurement units | Information source |
|---------------------------|------------------|-------------------|-------------------|
| Safety (SAF)              | We imply that data from animal and human studies support no apparent risk of enhanced disease in vaccines by safety. Adverse event profile supports advancement to the subsequent phase | 0–100 rating score | CDC, FDA |
| Efficacy (VEF)            | Evidence that the selected dose induces adequate immune responses in humans that might confer protection. | 1–100 rating score | CDC, WHO |
| Effectiveness (EFF)       | The ability in preventing COVID-19 disease depends on its potency and proper administration to individuals capable of responding | 1–100 rating score | WHO |
| Stability (STA)           | Stability data are sufficient to assure delivery of dose to be tested | 0–100 rating score | WHO |
ability to disaggregate preferences of DM from holistic decisions. The GA generates an initial population conforming to decision variables which are then converted into inter-criteria parameters (see Figure 1). Each element in the population is evaluated by its fitness, which concerns the set of inter-criteria parameters that better represent the decision-making’s preference when the set is used to construct the fuzzy outranking relation, then used in a multi-criteria classification. Once the GA has passed through all

```python
import random
import numpy as np

def create_reference_solution(chromosome_length):
    number_of_ones = int(chromosome_length / 2)
    reference = np.zeros(chromosome_length)
    reference[0: number_of_ones] = 1
    np.random.shuffle(reference)
    return reference

def create_starting_population(individuals, chromosome_length):
    population = np.zeros((individuals, chromosome_length))
    for i in range(individuals):
        ones = random.randint(0, chromosome_length)
        population [i, 0:ones] = 1
        np.random.shuffle(population[i])
    return population

def calculate_fitness(reference, population):
    identical_to_reference = population == reference
    fitness_scores = identical_to_reference.sum(axis=1)
    return fitness_scores

def select_individual_by_tournament(population, scores):
    population_size = len(scores)
    fighter_1 = random.randint(0, population_size-1)
    fighter_2 = random.randint(0, population_size-1)
    fighter_1_fitness = scores[fighter_1]
    fighter_2_fitness = scores[fighter_2]
    if fighter_1_fitness >= fighter_2_fitness:
        winner = fighter_1
    else:
        winner = fighter_2
    return population [winner, :]

def breed_by_crossover (parent_1, parent_2):
    chromosome_length = len(parent_1)
    crossover_point = random.randint(1, chromosome_length-1)
    child_1 = np.hstack((parent_1[0:crossover_point],
                         parent_2[crossover_point:]))
    child_2 = np.hstack((parent_2[0:crossover_point],
                         parent_1[crossover_point:]))
    return child_1, child_2

def randomly_mutate_population(population, mutation_probability):
    random_mutation_array = np.random.random(
        size=(population.shape))
    random_mutation_boolean = \
        random_mutation_array <= mutation_probability
    population[random_mutation_boolean] = \
        np.logical_not(population[random_mutation_boolean])
    return population
```

FIGURE 1  Simple genetic algorithm adapted from Sheppard (2017)
3.2.2 | Procedure of the ELECTRE III-GA

We consider the following steps to derive GA intercriteria parameters for our proposed ELECTRE III-GA model.

**Phase 1:** Prepare the input data. Input data refers to the problem, which is the performance matrix and DM preference. The DM generates holistic judgments from the paired alternatives (a_b) or as an order of alternatives. Also, the DM establishes criteria importance, ordering the best criterion on the first position and the worst criterion on the last position.

**Phase 2:** Run the GA. The GA includes the ELECTRE III method to aggregate DM preference, constructing a valued outranking relation named preferential model. The GA applies the genetic operators and evolves the population in each iteration. The fitness function of the GA is Kendall’s rank correlation index.

**Phase 3:** Consider the inter-criteria parameters as output data. The outcomes of GA show the best population. This results in different sets of inter-criteria parameters, which generates a ranking corresponding to the preferences of the DM.

3.3 | TOPSIS approach

The second multi-criteria approach we use to evaluate coronavirus vaccine candidates is TOPSIS. Introduced in 1981, TOPSIS is based on picking an ideal and an anti-ideal solution and comparing the distance of each one of the alternatives to those (Chen & Hwang, 1992).

3.4 | Proposed model

As described previously, the search to find a vaccine against COVID-19 consists of two subprocesses: selecting and ranking problems. In this paper, vaccines candidates against the novel coronavirus have been studied. The proposed approach to solve this problem is based on three major steps: (1) Description of the multi-criteria ranking problem, (2) Derivation of intercriteria parameters, and (3) Ranking of the preference order. To implement the first and second steps, the ELECTRE III-GA model is used, while the last step involves TOPSIS methodology, as shown in Figure 2.

4 | EMPIRICAL CASE STUDY

The next instance of the ranking problem discusses an empirical study of the following actual selection and ranking problem.
4.1 Sample data and decision making

Sample data involves 108 COVID-19 vaccine candidates in clinical trials extracted from six major databases, including WHO, U.S. National Library of Medicine, Chinese Clinical Trial Registry, Pan African Clinical Trials Registry, EU Clinical Trials Register, and Australian New Zealand Clinical Trials Registry (ANZCTR) websites as 30 July 2021. Those 108 applicants are labelled as A1, A2,..., A108. In addition, we have conducted personal online interviews with six professionals, including a medical doctor, a public health nurse, and four University students. The medical doctor is a graduate of the University of Notre Dame. He trained in internal medicine at the University of Southern California. He is a clinical associate professor at Florida State University College of Medicine. The second participant worked as a frontline health employee at Little Haiti Health Center for more than 10 years. The university students are all from Taiwan.

4.2 Threshold values and criteria weights

Using the original ELECTRE method, performance matrix, thresholds, weights (relative importance of the criteria), and final ranking were calculated and presented in this subsection. The DM was supported in defining its preferences and uncertainties through the indifference threshold ($q$), the preference threshold ($p$), and the veto threshold ($v$) for all five criteria by using a linear format. We define two columns of numeric values for each threshold, one for the slope (label beginning by alpha) and another for the interception (label beginning by beta), as shown in Table 2.

Evaluation and prioritisation of COVID-19 candidate vaccines developed by WHO are considered here. We complete the data preparation by imposing a direction of evaluation for each criterion and a direction of definition for each threshold, as shown in Table 3. All applicants were also evaluated by the experts using the criteria and scale. All criteria were treated as quantitative ones.

5 RESULTS AND DISCUSSIONS

5.1 Derivation of intercriteria parameters and outranking using ELECTRE III-GA process

Based on the additional information pointed out, we applied ELECTRE III to construct a fuzzy outranking relation. The credibility matrix indicates the reliability of the outranking hypothesis. Suppose the concordance index is greater than or equal to the discordance index for all criteria. In that case, the degree of credibility is equal to the concordance index. If the concordance index is strictly lower than the discordance index, then the degree of credibility is equal to the concordance index lowered to the importance of these discordances. Then, each alternative is linked with the other alternative with two arrows related to the credibility index. The distillation procedure is then used to outrank the alternatives. The name distillation has been chosen for the analogy with alchemists, who distill liquid mixtures to extract a magic ingredient. Moreover, we used Python to run the GA to exploit the outranking relation and derive a final ranking of the alternatives in decreasing the order of preferences. The computation in the GA was realised with the following parameters: chromosome_length = 10; population_size = 47; maximum_generation = 200. Final results can be presented as follows: A10 ($P = 46; NP = 0$), A16 ($P = 44; NP = 1$) and A41 ($P = 44; NP = 1$) having the least non-preference score are at the most preferable alternatives while A42 ($P = 1; NP = 43$), A44 ($P = 1; NP = 44$) and A26 ($P = 0; NP = 46$) are considered as the least preferable alternatives. Alternatives like A7, A9, A33, and A37 share the same preference score of 40 ($P = 40$). Likewise, labels A1, A5, A8, A36, and A38 are preferred 35 times compared to other alternatives. A preference score of 21 is shared between labels A15, A17, and A46, while alternatives A27, A40, and A46 are preferred 15 times compared to others (Table 4).

5.2 Ranking results by TOPSIS method

From the ELECTRE III-GA model, we extracted 15 actions based on Preference ($P > 30$) and Non-preference ($NP < 15$), as presented in Table 5. Then, we used Excel Spreadsheet to determine the weighted normalised decision matrix and Python compiler to plot the Ideal and anti-ideal solutions (Figure 3).

Table 6 ranks the novel coronavirus vaccines. According to our model, the best COVID-19 vaccine is BNT162b2, with a relative

| Criterion | $q$ | $\beta q$ | $\alpha p$ | $\beta p$ | $\alpha v$ | $\beta v$ |
|-----------|-----|----------|----------|----------|----------|----------|
| C1. Safety (SAF) | 0.08 | -2000 | 0.13 | -3000 | 0.9 | 50,000 |
| C2. Efficacy (VEF) | 0.02 | 0 | 0.05 | 0 | 0 | 0 |
| C3. Effectiveness (EFF) | 0.1 | -0.5 | 0.2 | -1 | 0.5 | 3 |
| C4. Stability (STA) | 0 | 3 | 0 | 5 | 0 | 15 |

| Criterion | Weight | Criteria evaluation direction | Threshold direction |
|-----------|--------|-------------------------------|---------------------|
| SAF | 2.5 | 1 | -1 |
| VEF | 2.5 | 1 | 1 |
| EFF | 1.0 | 1 | 1 |
| STA | 1.5 | 1 | 1 |

Table 2: Threshold values

Table 3: Evaluation/threshold direction and criteria weights
It is designed by Pfizer, one of the world's largest pharmaceutical companies, based in New York, collaborating with German biotech company BioNTech. This vaccine candidate is based on the injection of extracts of the genetic material of a virus, in this case, messenger RNA (mRNA), into human cells. It stimulates the production of viral proteins that mimic the coronavirus, causing the immune system to recognise its presence. Any successful vaccine based on this technology would be the first mRNA vaccine approved for human use. This vaccine requires two doses 21 days apart.

The second-best vaccine showed a relative closeness of 0.92. It was introduced by the Massachusetts-based biotech company, Moderna Therapeutics in collaboration with the National Institutes of Health under the name mRNA-1273. This vaccine candidate also relies on injecting snippets of mRNA into human cells to trigger an immune response. This vaccine requires two doses, 4 weeks apart.

JNJ-78436735 (relative closeness of 0.80) is the third-best vaccine against COVID-19. It is implemented by Johnson & Johnson, one of the world's largest multinational corporations, based in New Jersey, specialising in healthcare and pharmaceutical products. Johnson & Johnson is developing an adenovector vaccine, which introduces a piece of DNA from SARS-CoV-2 into the common cold-causing adenovirus that has been genetically changed so that it cannot replicate in the body. This vaccine builds on the technology Johnson & Johnson used to develop an Ebola vaccine and vaccine candidates for Zika and HIV.

With a relative closeness of 0.80, UB-612, which is the fourth-best vaccine candidate, consists of the Spike protein S1 subunit Receptor Binding Domain (RBD) genetically fused to a single chain Fc domain of human IgG1 (S1-RBD-sFc), combined with proprietary peptides representing T helper (Th) and cytotoxic T-cell (CTL) epitopes on S2 subunit, Membrane and Nucleocapsid structural protein components of SARS-CoV-2. It was built by COVAXX, a subsidiary of United Biomedical Inc (UBI) headquartered in the United States, in collaboration with German biotech company BioNTech Asia. COVAXX said the trial is partly supported by a grant from the Ministry of Health and Welfare in Taiwan of up to NTD 430 million (approximately $15 million). It is important to notice how well Taiwan Government's response to COVID-19 spread. Taiwan has until now contained the spread of Covid-19.

A biotechnology company named Novavax and based in Gaithersburg, Maryland, introduced the NVX-CoV2373. Novavax (relative closeness of 0.79) has bioengineered the coronavirus spike proteins, the parts that help the virus invade cells but cannot replicate or cause COVID-19. Its vaccine candidate combines those proteins into a

TABLE 4  Summary of outranking matrix

| Label | Vaccine or trial name | P | NP | R |
|-------|-----------------------|---|----|---|
| A10   | BNT162                | 46| 0  | 0 |
| A16   | INO-4800              | 44| 1  | 0 |
| A41   | UB-612                | 44| 1  | 0 |
| A7    | JNJ-78436735          | 40| 3  | 0 |
| A9    | mRNA-1273             | 40| 3  | 0 |
| A33   | COVAX-19              | 40| 3  | 0 |
| A37   | FINLAY-FR-1           | 40| 3  | 0 |
| A1    | CoronaVac             | 35| 7  | 1 |
| A5    | Ad5-nCoV              | 35| 7  | 1 |
| A8    | NVX-CoV2373           | 35| 7  | 1 |
| A36   | FINLAY-FR-2           | 35| 7  | 1 |
| A38   | EpiVacCorona          | 35| 7  | 4 |
| A34   | ACTRN12620000674932   | 34| 12 | 0 |
| A18   | ZyCoV-D               | 33| 13 | 0 |
| A20   | Covaxin               | 32| 14 | 0 |
| A45   | LNP-nCoVsaRNA         | 31| 15 | 0 |
| A47   | ACTRN0450004          | 25| 16 | 5 |
| A2    | ACTRN0453010          | 25| 16 | 1 |
| A3    | BBIBP-CovV            | 25| 16 | 1 |
| A21   | ACTRN04473690         | 25| 16 | 1 |
| A28   | GRAd-COV2             | 25| 16 | 1 |
| A35   | MVC-COV1901           | 25| 16 | 1 |
| A29   | ACTRN04552366         | 24| 22 | 0 |
| A15   | ChiCTR2000039462      | 21| 23 | 0 |
| A17   | Covidvax              | 21| 23 | 0 |
| A25   | ACTRN12620000817943   | 21| 23 | 0 |
| A23   | ACTRN0468305          | 19| 26 | 1 |
| A12   | CVnCoV                | 18| 26 | 2 |
| A13   | ACTRN04470609         | 18| 27 | 1 |
| A27   | ACTRN04591717         | 15| 29 | 0 |
| A40   | ACTRN04546841         | 15| 29 | 0 |
| A46   | ChiCTR2000034112      | 15| 29 | 0 |
| A30   | VXA-CoV2-1            | 14| 32 | 0 |
| A11   | ACTRN04466085         | 11| 33 | 2 |
| A14   | QazCovid-in           | 11| 33 | 1 |
| A22   | ACTRN04537208         | 11| 33 | 1 |
| A31   | ACTRN04569383         | 10| 36 | 0 |
| A32   | ACTRN0405908          | 9 | 37 | 0 |
| A24   | LUNAR-COV19 (ARCT-021)| 7 | 38 | 0 |
| A39   | ChiCTR2000037518      | 7 | 38 | 0 |
| A43   | ACTRN0497298          | 6 | 40 | 0 |
| A6    | Sputnik V             | 4 | 41 | 1 |
| A4    | AZD1222               | 3 | 41 | 2 |
| A19   | GX-19                 | 2 | 42 | 2 |
| A42   | V590                  | 1 | 43 | 2 |

Note: R means that an alternative a is not comparable to other alternatives; P refers to the preference of an alternative over the other alternatives; NP means how an alternative a is not preferred to the others.

_____

TABLE 4  (Continued)

| Label | Vaccine or trial name | P | NP | R |
|-------|-----------------------|---|----|---|
| A44   | ChiCTR2000037782      | 1 | 44 | 1 |
| A26   | bacTRL-Spike          | 0 | 46 | 0 |

(Continues)
knucklebone-shaped nanoparticle. This can be injected with its proprietary Matrix-M adjuvant—a compound that stimulates immune cells—to elicit an immune response. The vaccine is administered in two doses, 21 days apart.

INO-4800 (relative closeness: 0.79), introduced by the American biotechnology company, Inovio Pharmaceuticals is the sixth-best vaccine candidate against COVID-19 according to our model. It is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2. This vaccine contains the plasmid pGX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2.

### TABLE 5  Input data extracted from ELECTRE III-GA computation

| Criteria | Weight | Safety 0.25 | Efficacy 0.25 | Effectiveness 0.25 | Stability 0.25 |
|----------|--------|-------------|---------------|-------------------|---------------|
| Input alternatives |
| A10 | BNT162 | 99 | 98 | 95 | 90 |
| A16 | INO-4800 | 99 | 96 | 90 | 85 |
| A41 | UB-612 | 95 | 96 | 90 | 95 |
| A7 | JNJ-78436735 | 99 | 95 | 95 | 90 |
| A9 | mRNA-1273 | 95 | 95 | 90 | 90 |
| A33 | COVAX-19 | 95 | 95 | 90 | 80 |
| A37 | FINLAY- FR-1 | 97 | 95 | 90 | 90 |
| A1 | CoronaVac | 96 | 94 | 95 | 80 |
| A5 | Ad5-nCoV | 99 | 94 | 90 | 90 |
| A8 | NVX-CoV2373 | 98 | 94 | 90 | 95 |
| A36 | FINLAY- FR-2 | 95 | 94 | 90 | 90 |
| A38 | EpiVacCorona | 94 | 96 | 80 | 85 |
| A34 | ACTRN12620000674932 | 98 | 95 | 80 | 75 |
| A18 | ZyCoV-D | 94 | 94 | 80 | 75 |
| A20 | Covaxin | 90 | 93 | 80 | 85 |

### FIGURE 3  Ideal solution, anti-ideal solution, and closeness coefficient

6 | MANAGERIAL IMPLICATIONS

The proposed integrated evaluation framework can be used for a more effective assessment of coronavirus vaccines alternatives. Considering assessment is a multidimensional problem by its nature, a single model cannot explain the whole evaluation process for deciding on the most appropriate COVID-19 vaccine candidate. Our study combined safety, efficacy, stability, implementation, and availability attributes in a developed vaccine evaluation model to address this gap.

The reason for integrating ELECTRE and TOPSIS in our model is their strength in evaluating complex interrelationships among various aspects and handling internal dependencies (Sangaiah et al., 2017). To check its validity, the model is assessed by experts to understand its advantages and drawbacks better. The results align with (Bartsch et al., 2020), stating that the appropriate vaccine against the disease should be at least 80% effective.

This developed evaluation framework can help healthcare professionals and researchers, especially in developing countries, make proper judgments and gain research information by examining five criteria. Thus, the model does not simply follow a traditional approach and can provide decision-makers with a valuable tool to collect information in complex relationships that can be useful for the undecided.

This selection model provided in this study can be used worldwide. There are some differences that users should keep in mind when applying this model: the level of importance of the criteria may vary in different situations. This study can be helpful to researchers to understand this selection problem better theoretically and health officials to better design good evaluation systems.
7 | CONCLUSIONS AND FUTURE RESEARCH

7.1 | Conclusions

As the COVID-19 pandemic continues to challenge the global healthcare system, calling for the development of a safe and effective vaccine to protect against infection is urgent when we write this paper. Research institutions and pharmaceutical companies around the globe have already embarked on the race to develop COVID-19 vaccines, which are at different stages of development. World Health Organization and other databases identified more than 180 vaccines in pre-clinical development. This paper aims to evaluate those available vaccine alternatives and select the most suitable option. In decision and evaluation processes, there are many factors involving subjective and qualitative judgments and require different complex factors. In such processes, MCDM methods can be effectively employed to choose the most suitable COVID-19 vaccine correctly.

After performing a detailed state of the art and considering expert opinions, an evaluation model is developed. A hybrid MCDM approach based on ELECTRE III-Genetic Algorithm integrated with TOPSIS methodology is considered for selecting the most appropriate vaccine against the pandemic. The obtained results showed that BNT162b2 (Pfizer), mRNA-1273 (Moderna Therapeutics), JNJ-78436735 (Johnson & Johnson), UB-612 (COVAXX), and INO-4800 (Inovio) are ranking among the top and best vaccines against COVID-19 according to our model.

Table 6: Final ranking for the Covid-19 vaccines selection problem

| Vaccine name         | Origin            | $D_I$  | $D_J$  | $C_J$ | Result-rank |
|----------------------|-------------------|--------|--------|-------|-------------|
| BNT162               | Germany/China/USA | 0.00   | 0.07   | 0.96  | 1           |
| INO-4800             | USA/International | 0.01   | 0.05   | 0.79  | 6           |
| UB-612               | Taiwan/USA        | 0.01   | 0.05   | 0.80  | 4           |
| JNJ-78436735         | Belgium           | 0.01   | 0.05   | 0.80  | 3           |
| mRNA-1273            | USA               | 0.01   | 0.07   | 0.92  | 2           |
| COVAX-19             | Australia/South Korea | 0.02 | 0.05 | 0.76 | 7           |
| FINLAY-FR-1          | Cuba              | 0.03   | 0.04   | 0.61  | 8           |
| CoronaVac            | China             | 0.03   | 0.04   | 0.59  | 11          |
| Ad5-nCoV             | China             | 0.04   | 0.03   | 0.42  | 12          |
| NVX-CoV2373          | USA               | 0.01   | 0.05   | 0.79  | 5           |
| FINLAY-FR-2          | Cuba              | 0.03   | 0.04   | 0.60  | 9           |
| EpiVacCorona         | Russia            | 0.03   | 0.04   | 0.59  | 10          |
| ACTRN12620000674932  | Australia/USA     | 0.07   | 0.03   | 0.30  | 14          |

Thus, for these reasons, combining ELECTRE III-GA and TOPSIS provide successful results in reaching strategic decisions.

7.2 | Limitations and future research

Although we have shown an essential contribution to the literature, it is important to notice some limitations that future research can consider. First, the compilation of 108 vaccine alternatives following the WHO framework was systematic. Still, our assessment of the inclusion criteria is based on our subjective judgement. Therefore, some critical criteria such as supply chain, environment, and race are missing in this review. Future work can extend this framework by considering other criteria and other databases to perform assessment and evaluation on COVID-19 vaccines.

A second limitation is sensitivity analysis. A sensitivity analysis is essential to test the robustness of the results obtained from the decision model by varying the values of the weights and thresholds and observing the effect on the outcome. Subsequent work may consider adding a robustness test to check the overall validity of this model. These limitations can provide future research avenues and can step on the contributions established by this paper.

ACKNOWLEDGEMENTS

The authors are grateful to the anonymous referees for their most helpful suggestions that have improved the quality and legibility of this article.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES

Abdelwahab, S. F., Issa, U. H., & Ashour, H. M. (2021). A novel vaccine selection decision-making model (VSDMM) for COVID-19. Vaccine, 9(7), 718. Retrieved from https://www.mdpi.com/2076-393X/9/7/718

Abdullahi, I. N., Emeribe, U. A., Adekola, H. A., Abubakar, S. D., Dananga, A., Shuwa, H. A., Nwoba, S. T., Mustapha, J. O., Haruna, M. T., Olowookere, K. A., Animasaun, O. S., Ugwu, C. E., Onoja, S. O., Gadama, A. S., Mohammed, M., Daneji, I. M., Amadu, D. O., Gbamba, P. E., Onuigbo, N. B., Ahmad, A. E. (2021). Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: Prospects and challenges. Human Vaccines & Immunotherapeutics, 17(3), 620–637.

Aiello, G., La Scàlia, G., & Enea, M. (2013). A non-dominated ranking multi objective genetic algorithm and elector method for unequal area facility layout problems. Expert Systems with Applications, 40(12), 4812–4819. https://doi.org/10.1016/j.eswa.2013.02.026

Andrew, M. K., & McNeil, S. A. (2021). Influenza vaccination and the evolution of evidence-based recommendations for older adults: A Canadian perspective. Vaccine, 39, A36–A41. https://doi.org/10.1016/j.vaccine.2020.09.011

Angelis, A., Baltussen, R., & Tervonen, T. (2021). The need for novel approaches in assessing the value of COVID-19 vaccines. American Journal of Public Health, 111(2), 205–208. https://doi.org/10.2105/ajph.2020.306066

Bartsch, S. M., O’Shea, K. J., Ferguson, M. C., Bottazzi, M. E., Wedlock, P. T., Strych, U., McKinnell, J., Siegmund, S. S., Cox, S. N., Hotez, P. J., & Lee, B. Y. (2020). Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. American Journal of Preventive Medicine, 59(4), 493–503.

Batur Sir, G. D. (2021). Pain treatment evaluation in COVID-19 patients with hesitant fuzzy linguistic multicriteria decision-making. Journal of Healthcare Engineering, 2021, 1–11.

Begum, J., Mir, N. A., Dev, K., Buyamayum, B., Wani, M. Y., & Raza, M. (2021). Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. Transboundary and Emerging Diseases, 68(3), 1111–1124.

Carrillo, P. A., López, J. L., & Chavira, D. G. (2017). Deriving parameters and preferential model for a total order in ELECTRE III. Paper presented at the 2017 4th International Conference on Systems and Informatics (ICSIA).

Chen, P. (2021). Effects of the entropy weight on TOPSIS. Expert Systems with Applications, 168, 114186.

Chen, S.-J., & Hwang, C.-L. (1992). Fuzzy multiple attribute decision making methods Lecture notes in economics and mathematical systems, (pp. 289–486). Berlin, Heidelberg: Springer.

Chen, Y., Cheng, L., Lian, R., Song, Z., & Tian, J. (2021). COVID-19 vaccine research focuses on safety, efficacy, immunoinformatics, and vaccine production and delivery: A bibliometric analysis based on VOSviewer. BioScience Trends, 15, 64–73.

Clemente-Suárez, V. J., Navarro-Jiménez, E., Ruisoto, P., Dalamitos, A. A., Beltran-Velasco, A. I., Hormeño-Holgado, A., Laborde-Cárdenas, C. C., & Tomerno-Aguliera, J. F. (2021). Performance of fuzzy multi-criteria decision analysis of emergency system in covid-19 pandemic. An extensive narrative review. International Journal of Environmental Research and Public Health, 18(10), 5208. https://doi.org/10.3390/ijerph18105208

Cohen, C., White, J. M., Savage, E. J., Glynn, J. R., Choi, Y., Andrews, N., Brown, D., & Ramsay, M. E. (2007). Vaccine effectiveness estimates, 2004–2005 mumps outbreak, England. Emerging infectious diseases, 13(1), 12–17.

Dadari, I. K., & Zgibor, J. C. J. O. G. H. (2021). How the use of vaccines outside the cold chain or in controlled temperature chain contributes to improving immunization coverage in low-and middle-income countries (LMICs): A scoping review of the literature.

Dumka, N., Goel, K., Guo, Y., McFall, H., Pillai, A. R., Shukla, A., Repka, M. A. & Murthy, S. N. (2019). Stability of vaccines. AAPs PharmSciTech, 2021, 1–11. https://doi.org/10.1021/s2249-018-1254-2

Enayatkhani, M., Hasaniazad, M., Faezi, S., Gouklani, H., Davoodian, P., Ahmad, N., Einakian, M. A., Karmostaji, A., & Ahmad, K. (2021). Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: An in silico study. Journal of Biomolecular Structure and Dynamics, 39(8), 2857–2872.

Faasse, K., Newby, J. (2020). Public perceptions of covid-19 in australia: perceived risk, knowledge, health-protective behaviors, and vaccine intentions. Frontiers in Psychology, 11, 1–11. https://doi.org/10.3389/fpsyg.2020.551004

Figueira, J. R., Mousseau, V., & Roy, B. (2016). ELECTRE methods. In S. Greco, M. Ehrgott & J. R. Figueira (Eds.), Multiple criteria decision analysis (2nd ed., pp. 155–185). Springer.

Head, K. J., Kasting, M. L., Sturm, L. A., Hartsoc, J. A., & Zimet, G. D. (2020). A national survey assessing SARS-CoV-2 vaccination intentions: Implications for future public health communication efforts. Science Communication, 42(5), 698–723.

Hezam, I. M., Nayeem, M. K., Foul, A., & Araisheedi, A. F. (2021). COVID-19 vaccine: A neurosptic MCDM approach for determining the priority groups. Results in Physics, 20, 103654. https://doi.org/10.1016/j.rinp.2020.103654

Jahrak, J., Naik, S. S., & Prasad, S. (2021). COVID-19 vaccination prioritization for persons with severe mental illness. Asian Journal of Psychiatry, 64, 102792–102792. https://doi.org/10.1016/j.ajp.2021.102792

Khurana, A., Allwadhi, P., Khurana, I., Allwadhi, S., Weiskirchen, R., Banothu, A. K., Chhabra, D., Joshi, K., & Bhari, K. K. (2021). Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today, 38, 101142. https://doi.org/10.1016/j.jantod.2021.101142

Kumar, N., Admane, N., Kumari, A., Sood, D., Grover, S., Prajapati, V. K., Chandra, R., & Grover, A. (2021). Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework. Scientific Reports, 11(1), 7653. https://doi.org/10.1038/s41598-021-86986-6

Lee, C., Wedlock, P. T., Haidari, L. A., Elder, K., Potet, J., Manning, R., Connor, D. L., Spiker, M. L., Bonner, K., Rangarajan, A., Hunydh, D. & Brown, S. T. (2017). Economic impact of thermostable vaccines. Vaccine, 35(23), 3135–3142. https://doi.org/10.1016/j.vaccine.2017.03.081

Leyva-López, J. C., & Fernández-González, E. (2003). A new method for group decision support based on ELECTRE III methodology. European Journal of Operational Research, 148(1), 14–27. https://doi.org/10.1016/S0377-2217(02)00273-4

Majumder, P., Biswas, P., & Majumder, S. (2020). Application of new topsis approach to identify the most significant risk factor and continuous monitoring of death of covid-19. Electronic Journal of General Medicine, 17(6), 1–12. https://doi.org/10.29333/ejgm/7904

Malabadi, R. B., Meti, N. T., & Chalannavar, R. K. (2021). Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (COVID-19). International Journal of Research and Scientific Innovations, 8(2), 191–198.

Marchetti, D., & Wanke, P. (2020). Efficiency of the rail sections in Brazilian railway system, using TOPSIS and a genetic algorithm to analyse optimized scenarios. Transportation Research Part E: Logistics and Transportation Review, 135, 101858.

Mehrotra, D. V., Janes, H. E., Fleming, T. R., Annunziato, P. W., Neuzil, K. M., Carpp, L. N., Benkseer, D., Brown, E. R., Carone, M., Cho, I., Donnell, D., Fay, M. P., Fong, Y., Han, S., Hirsch, I., Huang, Y., Huang, Y., Hyrien, O., Juraska, M., & Gilbert, P. B. (2021). Clinical endpoints for evaluating efficacy in covid-19 vaccine trials. Annals of Internal Medicine, 174(2), 221–228. https://doi.org/10.7326/m20-6169
Mohammed, M. A., Abdulkareem, K. H., Al-Waisy, A. S., Mostafa, S. A., Al-Fahdawi, S., Dinar, A. M., Alhakami, W., Baz, A., Al-Mhiqani, M. N., Alhakami, H., Arbaiy, N., Maashi, M. S., Mutlag, A. A., Garcia-Zapirain, B., & De La Torre Diez, I. (2020). Benchmarking methodology for selection of optimal covid-19 diagnostic model based on entropy and topsis methods. *IEEE Access*, 8, 99115–99131. https://doi.org/10.1109/access.2020.2995597

Moore, S., Hill, E. M., Dyson, L., Tildesley, M. J., & Keeling, M. J. (2021). Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. *PLoS Computational Biology*, 17(5), e1008849. https://doi.org/10.1371/journal.pcbi.1008849

Ni, L., Chen, Y.-W., & de Brujin, O. (2021). Towards understanding socially influenced vaccination decision making: An integrated model of multiple criteria belief modelling and social network analysis. *European Journal of Operational Research*, 293(1), 276–289.

Nichols, M. K., Andrew, M. K., Hatchette, T. F., Ambrose, A., Boivin, G., Bowie, W., Chit, A., Dos Santos, G., ElSherif, M., Green, K., Haguinet, F., Halperin, S. A., Ibarguchi, B., Johnstone, J., Katz, K., Lagacé-Wiens, P., Langley, J. M., LeBlanc, J., Loeb, M., ... McNeil, S. A. (2018). Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). *Vaccine*, 36(16), 2166–2175. https://doi.org/10.1016/j.vaccine.2018.02.093

Orenstein, W. A., Bernier, R. H., Dondero, T. J., Hinman, A. R., Marks, J. S., Bart, K. J., & Sirotkin, B. (1985). Field evaluation of vaccine efficacy. *Bulletin of the World Health Organization*, 63(6), 1055–1068.

Oyarzun, P., Kashyap, M., Fica, V., Salas-Burgos, A., Gonzalez-Galarza, F. F., McCabe, A., Jones, A. R., Middleton, D., & Kobe, B. (2021). A proteome-wide immunoinformatics tool to accelerate t-cell epitope discovery and vaccine design in the context of emerging infectious diseases: an ethnicity-oriented approach. *Frontiers in Immunology*, 12, 1–25. https://doi.org/10.3389/fimmu.2021.598778

Rohaninejad, M., Kheirkhah, A., Fattahi, P., & Vahedi-Nouri, B. (2015). A hybrid multi-objective genetic algorithm based on the ELECTRE method for a capacitated flexible job shop scheduling problem. *The International Journal of Advanced Manufacturing Technology*, 77(1–4), 51–66.

Roy, B. (2013). *Multicriteria methodology for decision aiding* (Vol. 12). Springer Science & Business Media.

Saha, R., Ghosh, P., & Burra, V. P. (2021). Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches. *Biotech*, 11(2), 1–14.

Sangaiah, A. K., Gopal, J., Basu, A., Subramaniam, P. R., Sangaiah, A. K., Gopal, J., Basu, A. & Subramaniam, P. R. (2017). An integrated fuzzy DEMATEL, TOPSIS, and ELECTRE approach for evaluating knowledge transfer effectiveness with reference to GSD project outcome. *Neural Computing and Applications*, 28(1), 111–123. https://doi.org/10.1007/s00521-015-2040-7

Sayan, M., Sarigul Yildirim, F., Sanlidag, T., Uzun, B., Uzun Ozsahin, D., & Ozsahin, I. (2020). Capacity evaluation of diagnostic tests for COVID-19 using multicriteria decision-making techniques. *Computational and Mathematical Methods in Medicine*, 8, 1560250. https://doi.org/10.1155/2020/1560250

Sheppard, C. (2017). *Genetic algorithms with python*. Smashwords Edition.

Vafaeinejad, A. (2016). Cropping pattern optimization by using of TOPSIS and genetic algorithm based on the capabilities of GIS. *Iranian journal of Ecohydrology*, 3(1), 69–82.

Whelan, S. F. (2009). Mortality in Ireland at advanced ages, 1950-2006: Part 1: Crude rates. *Annals of Actuarial Science*, 4(1), 33–66.

World Health Organization. (2018). *Controlled temperature chain (CTC)-beyond the traditional cold chain*. Author.

How to cite this article: Forestal, R. L., & Pi, S.-M. (2022). A hybrid approach based on ELECTRE III-genetic algorithm and TOPSIS method for selection of optimal COVID-19 vaccines. *Journal of Multi-Criteria Decision Analysis*, 29(1-2), 80–91. https://doi.org/10.1002/mcda.1772